

ACC Highlights 2025



Recorded Live On:
TUESDAY, APRIL 15,
2025

This program is intended for cardiovascular specialists and primary care physicians from across Canada.



Developed by:



ACC Highlights 2025

FACULTY



Milan Gupta

MD, FRCPC, FCCS, CPC(HC)
Assistant Professor, Department
of Medicine, University of Toronto
Medical Director, Canadian
Collaborative Research Network
Brampton, ON



Narendra Singh

MD, FRCPC, FCCS, FACC, FAHA
Director, NSC Cardiology
Clinical Assistant Professor,
Medical College of Georgia at
Augusta University and Mercer
University
Atlanta, GA

This program will cover the key clinical trial findings and their implications from ACC 2025. This program is intended for cardiovascular specialists and primary care physicians.

Discussion Topics:

- **SOUL** – Cardiovascular benefits of an oral GLP-1 receptor agonist
- **RIVAWAR** – Rivaroxaban vs. warfarin for acute LV thrombus post-MI
- **STRIDE** – Clinical effects of weekly semaglutide in patients with peripheral arterial disease
- **TAVR Updates** – The role of TAVR in aortic insufficiency and in low-risk aortic stenosis

Learning Objectives:

Following participation in this program, participants will be able to:

- Review trials and data presented at ACC 2025
- Examine where the data presented may impact clinical practice guidelines
- Apply the latest evidence-based strategies in clinical practice

This program was developed by CCRN and received an unrestricted educational grant from Novartis



Watch the OnDemand recording on CCRN
[Here](#)



CCRN
Canadian Collaborative Research Network

